Literature DB >> 10992368

Transurethral resection of the prostate among medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases.

J H Wasson1, T A Bubolz, G L Lu-Yao, E Walker-Corkery, C S Hammond, M J Barry.   

Abstract

PURPOSE: We examine the epidemiology and associated risks of transurethral resection of the prostate among Medicare beneficiaries for the period 1984 to 1997.
MATERIALS AND METHODS: We used hospital claims for transurethral resection of the prostate from a 20% national sample of Medicare beneficiaries for the period 1991 to 1997. Risk of mortality and reoperation were evaluated using life table methods and compared to those for the period 1984 to 1990. We also examined the association between surgical volume and adverse outcomes following resection using unique urologist identifier codes from the 1997 part B Medicare claims.
RESULTS: Compared to 1984 to 1990, age adjusted rates of transurethral resection for benign prostatic hyperplasia (BPH) during 1991 to 1997 declined by approximately 50% for white (14.6 to 6.72/1,000) and 40% for black (11.8 to 6.58/1,000) men. Of the men who underwent resection for BPH during the recent period 53% were 75 years old or older but 30-day mortality in men 70 years old or older was significantly lower than that in 1984 to 1990. Since 1987 the 5-year risk for reoperation following transurethral resection for BPH has remained 5%. For resection performed in 1997 we observed no statistically significant association between urologist surgical volume and risks of reoperation or 30-day mortality.
CONCLUSIONS: Compared to the peak period of its use in the 1980s, older men are now undergoing transurethral resection of the prostate. Nevertheless, outcomes for men 65 years old or older continue to be good.

Entities:  

Mesh:

Year:  2000        PMID: 10992368

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

Review 1.  Changes in medicare reimbursement: impact on therapy for benign prostatic hyperplasia.

Authors:  Robert F Donnell
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 3.092

2.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

3.  The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.

Authors:  David A Taub; John T Wei
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

4.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

Review 5.  Holmium Laser Enucleation of the Prostate: Patient Selection and Outcomes.

Authors:  Joseph M Kuebker; Nicole L Miller
Journal:  Curr Urol Rep       Date:  2017-10-19       Impact factor: 3.092

6.  National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008).

Authors:  Bahaa S Malaeb; Xinhua Yu; A Marshall McBean; Sean P Elliott
Journal:  Urology       Date:  2012-05       Impact factor: 2.649

7.  Contemporary practice patterns of endoscopic surgical management for benign prostatic hyperplasia among urologists in the United States.

Authors:  William T Lowrance; Andrew Southwick; Alexandra C Maschino; Jaspreet S Sandhu
Journal:  J Urol       Date:  2012-12-03       Impact factor: 7.450

8.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

Review 9.  [Benign prostatic hyperplasia (BPH) : Surgical therapy options].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; S Walther; C Stief
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 10.  How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?

Authors:  Ricardo R Gonzalez; Alexis E Te
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.